Paasa Logo
Kissei Pharmaceutical Co., Ltd. logo
4547JPXMarket closedOpens 9:00am JST

Kissei Pharmaceutical Co., Ltd.

¥3,890.00Last updated
-¥115.00 (2.87%)Past day
Timezone

Kissei Pharmaceutical Co., Ltd. (JPX: 4547) is trading at ¥3,890.00, about ₹2,369 at today's JPY/INR rate, as of 28 Sep 2026, 2:30 AM ET, down 2.87% today. Indian residents can buy Kissei Pharmaceutical from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:¥3,925.00
Previous close:¥4,005.00
Volume:205.90K

Today's low

¥3,870.00

Today's high

¥3,940.00

52 week low

¥3,500.00

52 week high

¥5,040.00

4547 opened at ¥3,925.00, closed previously at ¥4,005.00, and has traded between ¥3,500.00 and ¥5,040.00 over the past 52 weeks.

About

Kissei Pharmaceutical Co., Ltd. specializes in the discovery, development, production, and commercialization of pharmaceutical products, with a primary focus on the Japanese market. Its marketed pharmaceuticals encompass Urief and Urief OD tablets, designed to alleviate dysuria. For type 2 diabetes, it provides Glufast, Glubes, and Marizev tablets. Treating renal anemia, the company offers Darbepoetin Alfa BS and Epoetin Alfa BS injections. Beova tablets are available for managing overactive bladder, while hyperphosphatemia patients can utilize P-TOL chewable tablets. Furthermore, Minirin Melt OD tablets address a range of conditions including nocturia caused by nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis stemming from reduced urine osmolality. Kissei maintains a robust product pipeline, featuring KPS-0373, which has successfully completed Phase III clinical trials for spinocerebellar ataxia, and CCX168, also a completed Phase III candidate, targeting microscopic polyangiitis and granulomatosis with polyangiitis. Currently undergoing Phase III trials are AJM300 for ulcerative colitis, R788 for chronic idiopathic thrombocytopenic purpura, and MR13A9 to alleviate uremic pruritus in dialysis patients. Other investigational compounds include KLH-2109 for endometriosis and uterine fibroids, KDT-3594 for Parkinson's disease, Silodosin addressing dysuria linked to benign prostatic hyperplasia, Mitiglinide for type 2 diabetes mellitus, and Bedoradrine for the management of acute asthma exacerbations. Beyond its pharmaceutical endeavors, Kissei also manufactures and markets specialized nutritional products, such as protein-controlled and energy-supplying foods, and engages in the procurement and sale of associated raw materials. Furthermore, the company extends its operations to include system development, information processing, construction services, equipment and facility oversight, alongside information collection and development assistance. Founded in 1946 as Kissei Yakuhin Kogyo Co., Ltd., the company adopted its present name, Kissei Pharmaceutical Co., Ltd., in October 1964. Its corporate headquarters are situated in Matsumoto, Japan.

Country
JP
CEO
Mutsuo Kanzawa
Exchange listed on
JPX
Industry
Drug Manufacturers - Specialty & Generic
Base currency
JPY
Full Time Employees
1,786
Sector
Healthcare
IPO date
01/01/2001

Key statistics

Avg. volume

110.11K

Market cap

¥161.25B

P/E Ratio

11.53

Price-to-sales ratio

1.64

Enterprise value

¥132.33B

Free cash flow yield

0.00%

Debt-to-equity ratio

0.01

Return on equity

6.31%

ROIC

-1.27%

Beta

0.25

Dividend yield

4.11%

Last dividend

¥160.00

Financial overview

Revenue

¥97.41B

Earnings per share

¥331.53

Free cash flow

-¥6.37B

Net profit margin

14.18%

Gross margin

46.83%

EBITDA

¥21.56B

Revenue growth

10.28%

Similar securities

This is not an investment recommendation

How to buy Kissei Pharmaceutical from India

Indian residents can buy Kissei Pharmaceutical shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to JPY.

  3. Search for Kissei Pharmaceutical and place an order

    Find Kissei Pharmaceutical by name or by its ticker, 4547, and choose an order type. The Tokyo Stock Exchange typically trades in units of 100 shares. Kissei Pharmaceutical trades 5:30 am – 12:00 pm IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Kissei Pharmaceutical position in JPY and INR, and use Paasa's capital-gains and dividend statements when you file your Indian return.

Read the full guide: how to invest in Kissei Pharmaceutical from India

Trading and taxes when buying Kissei Pharmaceutical from India

Trading and limits

Trading hours
9:00 am – 3:30 pm JST
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
Slab rateDividends are taxed at your slab rate in India. Japan withholds a preferential 10% on dividends for Indian residents under the India–Japan DTAA rather than the higher domestic rate, and the tax withheld can be claimed as a foreign tax credit in India. Kissei Pharmaceutical’s current yield is 4.11%.Dividend tax explained
Estate or inheritance tax
May applyJapan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir.Estate tax explained

Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

FAQs

Can Indian residents buy Kissei Pharmaceutical stock?

Yes. Kissei Pharmaceutical (4547) has been listed on the Tokyo Stock Exchange since 2001, in the Drug Manufacturers - Specialty & Generic industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to JPY. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

How much does one Kissei Pharmaceutical share cost in rupees?

One Kissei Pharmaceutical share is ¥3,890.00 — about ₹2,369 at a JPY/INR rate of 0.6091 on 27 Sep 2026. Both the Kissei Pharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Kissei Pharmaceutical from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

What is the minimum I can buy of Kissei Pharmaceutical?

The Tokyo Stock Exchange typically trades in units of 100 shares.

How are gains on Kissei Pharmaceutical shares taxed in India?

Japan generally does not levy capital gains tax on non-resident individual investors, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the JPY/INR rate on the purchase and the sale date, so the rupee move counts alongside the Kissei Pharmaceutical price. Paasa issues a capital-gains statement for your return.

Does Kissei Pharmaceutical pay a dividend, and how is it taxed in India?

Yes. Kissei Pharmaceutical pays a dividend and the current yield is 4.11%; the last declared dividend was ¥160.00 per share, about ₹97.46. Dividends are taxed at your slab rate in India. Japan withholds a preferential 10% on dividends for Indian residents under the India–Japan DTAA rather than the higher domestic rate, and the tax withheld can be claimed as a foreign tax credit in India. Paasa's dividend report lists the gross dividend and any tax withheld for each payment.

When can I trade Kissei Pharmaceutical from India?

The Tokyo Stock Exchange trades 5:30 am – 12:00 pm IST in Indian time. It also halts for lunch, 8:00 am – 9:00 am IST. Orders can only execute during that window.

Is there estate or inheritance tax on Kissei Pharmaceutical shares held from India?

Japan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir. It applies to your overall holdings in that jurisdiction rather than to any one position.

Do I have to declare Kissei Pharmaceutical shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Kissei Pharmaceutical holding, its cost and its closing value.

How do I sell Kissei Pharmaceutical and bring the money back to India?

You sell during market hours (5:30 am – 12:00 pm IST) and the proceeds settle in JPY in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.